CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
Rhea-AI Summary
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced it will release its annual 2024 financial results after market close on March 4, 2025, followed by a conference call at 4:30 p.m. Eastern Time.
The specialty pharmaceutical company maintains a portfolio of FDA-approved brands including:
- Acetadote® for acetaminophen poisoning
- Caldolor® for pain and fever
- Kristalose® for constipation
- Sancuso® for chemotherapy-related nausea
- Vaprisol® for hyponatremia
- Vibativ® for bacterial infections
Additionally, Cumberland has Phase II clinical programs ongoing for its ifetroban candidate, targeting Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Positive
- Diverse portfolio of 6 FDA-approved products
- Multiple Phase II clinical trials in progress
- Strategic focus on three distinct market segments
Negative
- None.
News Market Reaction
On the day this news was published, CPIX gained 6.57%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on
SOURCE: Cumberland Pharmaceuticals Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-annual-2024-financial-results-302384710.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release its 2024 annual financial results?
How many FDA-approved products does Cumberland Pharmaceuticals (CPIX) currently have in its portfolio?
What clinical trials is Cumberland Pharmaceuticals (CPIX) currently conducting with ifetroban?
What market segments does Cumberland Pharmaceuticals (CPIX) focus on?
